This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

SAVOR-TIMI 53

The SAVOR-TIMI 53 CVOT assessed the cardiovascular effect of saxagliptin in patients with type 2 diabetes with high CV risk, or prior CV events. This module details the results.

SAVOR-TIMI 53
Rate this content
  • SAVOR-TIMI 53
  • SAVOR-TIMI 53: trial design
  • SAVOR-TIMI 53: baseline characteristics
  • SAVOR-TIMI 53: CV disease at baseline
  • SAVOR-TIMI 53: kidney function at baseline
See More
Do you want to go to the Presentation Builder section to create a new presentation?
Cancel Go
Cancel